ORETCR: Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance
Study Details
Study Description
Brief Summary
-
Clopidogrel resistance is common in patients of ischemic cerebrovascular disease.
-
Genetic polymorphisms are the most important factors to clopidogrel resistance.
-
The purpose of this study is to find the genes which are the related to clopidogrel resistance.
-
Through gene sequencing, we can filter patient of clopidogrel resistance, so another drug maybe used to avoid the undesired efficacy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- genotype, platelet aggregation rate, cerebrovascular events [2 years]
Genotype means the genetic polymorphism of ABCB1, CES, CYP2C19, PON1, P2RY12, which can be determined through gene sequencing.
Secondary Outcome Measures
- Active metabolite concentration [2 years]
Active metabolite concentration depend on the genetic polymorphism.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
symptomatic ischemic cerebrovascular disease caused by Intracranial atherosclerotic atherosclerosis research database.
-
90 days had a stroke or transient ischemic attack is defined as symptomatic Intracranial atherosclerotic atherosclerosis
-
stenosis ≥ 50% (MRI or CT angiography).
-
Intracranial vascular stenosis measured according to the method reported Warfarin aspirin symptomatic intracranial disease research.
Exclusion Criteria:
-
diffuse intracranial arterial stenosis.
-
cranial magnetic resonance imaging shows lesions as the branch artery blockage caused.
-
non-atherosclerotic lesions.
-
occurred within 6 weeks of vascular lesions in the region of intracranial hemorrhage.
-
potential cardiac thrombus source.
-
has concurrent intracranial tumors, intracranial aneurysm or arteriovenous malformation.
-
ipsilateral extracranial carotid or vertebral artery stenosis ≥ 50%;
-
known to heparin, aspirin, clopidogrel, anesthetics and contrast agents contraindications;
-
hemoglobin less than 10g/dL, platelet count <100000/dL;
-
responsibility left after cerebral vascular-related serious neurological dysfunction (mRS ≥ 3);
-
international normalized ratio> 1.5
-
there are factors that can not be corrected by bleeding;
-
life expectancy <1 year;
-
pregnant or lactating women;
-
indications Commission determines that the patient is not suitable for the study treatment.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Zhongrong Miao
Investigators
- Study Director: Ning Ma, Doctor, Beijing Tiantan Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BTH-GENE-CR